As of November 27, 2023, the average one-year price target for Arvinas is 55.14. The forecasts range from a low of 20.20 to a high of $99.75. The average price target represents an increase of 137.98% ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump ...

Investors in Arvinas Inc (Symbol: ARVN) saw new options become available this week, for the July 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Shares of Arvinas, Inc. (ARVN) have gained 13.9% over the past four weeks to close the last trading session at $7.39, but there could still be a solid upside left in the stock if short-term price ...

Fintel reports that on January 6, 2026, Citigroup upgraded their outlook for Arvinas (NasdaqGS:ARVN) from Neutral to Buy.

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, reached an all-time high of $108 in July of this year ...

The U.S. had a Christmas gift for each of the men in South Viet Nam’s 1st Regiment of the 1st Division, based just south of the Demilitarized Zone. It was the lightweight, fast-firing M-16 rifle, ...

AR VN RVN stock from one of the Wall Street analysts, citing development challenges for its cancer treatment - ARV-471. Larger pharmaceutical companies, Sanofi and Roche, have seen failures in their ...